Heparanase-2 Expression in Normal Ovarian Epithelium and in Benign and Malignant Ovarian Tumors

被引:13
|
作者
de Moura, Joel Pereira, Jr. [1 ]
Nicolau, Sergio Mancini [1 ]
Stavale, Joao Norberto [2 ]
da Silva Pinhal, Maria Aparecida [3 ]
de Matos, Leandro Luongo [4 ]
Baracat, Edmund Chada [1 ]
de Lima, Geraldo Rodrigues [1 ]
机构
[1] Univ Fed Sao Paulo, Dept Gynecol, Escola Paulista Med, BR-04037005 Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Dept Pathol, Escola Paulista Med, BR-04037005 Sao Paulo, Brazil
[3] Univ Fed Sao Paulo, Dept Biochem, Escola Paulista Med, BR-04037005 Sao Paulo, Brazil
[4] ABC Fdn, Dept Biochem, Mol Biol Lab, Fac Med, Sao Paulo, Brazil
关键词
Ovarian neoplasia; Heparanase; 2; Extracellular matrix; Heparan sulfate; Proteoglycans; MAMMALIAN HEPARANASE; BASEMENT-MEMBRANES; SULFATE; INVASION; METASTASIS; PERLECAN; CLONING; GROWTH;
D O I
10.1111/IGC.0b013e3181a834a2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Studies have highlighted the changes that take place in the environment between the cell and the extracellular matrix during the process of neoplastic expansion. Several papers have associated the expression of heparanase 1 with various malignant tumors. Heparanase 2 is probably related to loss of cell adhesion. Objective: The aim of this study was to evaluate the expression of heparanase 2 in epithelial neoplasia of the ovaries and in samples of normal ovarian tissue. Methods: Seventy-five ovary specimens were analyzed and divided into 3 groups: 23 malignant and 35 benign epithelial ovarian neoplasia and 17 without ovarian disease. We used 2 methodological techniques for evaluating the immunoexpression of heparanase 2. The first followed the qualitative criterion of positive or negative in relation to enzymatic expression, and the second involved computerized quantification of this expression, performed on the same slides. Results: In the quantitative analysis, we found positivity indices for heparanase 2 expression of 72.2% and 87.3% in the samples of benign and malignant neoplasias, respectively. In these,the intensity of expression and the expression index were 147.2 and 121.2. respectively, for the benign neoplasia and 134.1 and 118.0 for the malignant neoplasia. Qualitatively, its expression was strong or moderate in 44.2% of the benign and 78.2% of the malignant tumors; its expression in all of the nonneoplastic samples was negative, with the exception of one that was weakly positive. Conclusions: Heparanase 2 is involved in neoplastic proliferation, but it was not exclusively associated with the malignant process. Furthermore, there was no difference in its expression between benign and malignant ovarian epithelial neoplasia.
引用
收藏
页码:1494 / 1500
页数:7
相关论文
共 50 条
  • [31] Differential Nuclear Expression of Aurora A Kinase in Benign, Borderline, and Malignant Serous Ovarian Tumors
    Cratte, J. E.
    Sehultz, D. S.
    Inamdar, K. V.
    Lehman, N. L.
    MODERN PATHOLOGY, 2010, 23 : 238A - 238A
  • [32] Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors
    Zagorianakou, N
    Stefanou, D
    Makrydimas, G
    Zagorianakou, P
    Briasoulis, E
    Karavasilis, V
    Pavlidis, N
    Agnantis, NJ
    HISTOLOGY AND HISTOPATHOLOGY, 2006, 21 (4-6) : 341 - 347
  • [33] Differential Nuclear Expression of Aurora A Kinase in Benign, Borderline, and Malignant Serous Ovarian Tumors
    Crane, J. E.
    Schultz, D. S.
    Inamdar, K. V.
    Lehman, N. L.
    LABORATORY INVESTIGATION, 2010, 90 : 238A - 238A
  • [34] EXPRESSION OF ALPHA-SMOOTH MUSCLE ACTIN IN BENIGN OR MALIGNANT OVARIAN-TUMORS
    KOBAYASHI, H
    TSURUCHI, N
    SUGIHARA, K
    KAKU, T
    SAITO, T
    KAMURA, T
    TSUKAMOTO, N
    NAKANO, H
    TANIGUCHI, S
    GYNECOLOGIC ONCOLOGY, 1993, 48 (03) : 308 - 313
  • [35] Differences in p16 gene methylation and expression in benign and malignant ovarian tumors
    McCluskey, LL
    Chen, C
    Delgadillo, E
    Felix, JC
    Muderspach, LI
    Dubeau, L
    GYNECOLOGIC ONCOLOGY, 1999, 72 (01) : 87 - 92
  • [36] p14 expression differences in ovarian benign, borderline and malignant epithelial tumors
    Cabral, Vinicius Duarte
    Cerski, Marcelle Reesink
    Brito, Ivana Trindade Sa
    Kliemann, Lucia Maria
    JOURNAL OF OVARIAN RESEARCH, 2016, 9
  • [37] OCCURRENCE OF EPIDERMAL GROWTH-FACTOR RECEPTORS IN BENIGN AND MALIGNANT OVARIAN-TUMORS AND NORMAL OVARIAN TISSUES - AN IMMUNOHISTOCHEMICAL STUDY
    HENZENLOGMANS, SC
    VANDERBURG, MEL
    FOEKENS, JA
    BERNS, PMJJ
    BRUSSEE, R
    FIERET, JH
    KLIJN, JGM
    CHADHA, S
    RODENBURG, CJ
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1992, 118 (04) : 303 - 307
  • [38] Benign or malignant ovarian neoplasms and ovarian endometriomas
    Takahashi, K
    Kurioka, H
    Irikoma, M
    Ozaki, T
    Kanasaki, H
    Miyazaki, K
    JOURNAL OF THE AMERICAN ASSOCIATION OF GYNECOLOGIC LAPAROSCOPISTS, 2001, 8 (02): : 278 - 284
  • [39] TRANSITION FROM BENIGN TO MALIGNANT EPITHELIUM IN MUCINOUS AND SEROUS OVARIAN CYSTADENOCARCINOMA
    PULS, LE
    POWELL, DE
    DEPRIEST, PD
    GALLION, HH
    HUNTER, JE
    KRYSCIO, RJ
    VANNAGELL, JR
    GYNECOLOGIC ONCOLOGY, 1992, 47 (01) : 53 - 57
  • [40] A biomarker panel for distinguishing between malignant and benign ovarian tumors
    Ueland, F.
    Zhang, Z.
    Crutcher, G.
    Fung, E.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S98 - S99